MORE►
Santen U.S. organization
Marketing image for one of Eyevance Pharmaceuticals' products, Flarex. [eyevance.com]
Fort Worth Ophthalmic Biotech Eyevance Exits to Japanese Firm for $225M
by Alex Edwards | Sep 17, 2020
Eyevance Pharmaceuticals, which develops and commercializes ophthalmic products, has been purchased for $225 million by Santen, a Japanese leader in ophthalmology. Eyevance will join Santen's U.S. organization.
